Tag Archives: Supernus Pharmaceuticals

In the recent decision Supernus Pharmaceuticals, Inc. v. Iancu, the Federal Circuit held that the USPTO wrongly imposed a Patent Term Adjustment (PTA) to the applicant for an Information Disclosures Statement (IDS) filed after a Request for Continued Examination (RCE). Patent Term Adjustment Statute The PTA statute establishes that an award in patent term should […]